Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).
Noelle V. Frey(Hospital of the University of Pennsylvania), David L. Porter(Chapman University), Pamela A. Shaw(University of Pennsylvania), James K. Mangan(UC San Diego Health System), Katherine T. Marcucci(Translational Therapeutics (United States)), Bruce L. Levine(University of Pennsylvania), Saar Gill(Parker Institute for Cancer Immunotherapy), Simon F. Lacey(University of Pennsylvania), Shannon L. Maude(Children's Hospital of Philadelphia), Stephan A. Grupp(Children's Hospital of Philadelphia), Jan J. Melenhorst(Translational Therapeutics (United States)), Elizabeth O. Hexner(University of Pennsylvania), Carl H. June(University of Pennsylvania), Solveig G. Ericson, Selina M. Luger(University of Pennsylvania)
Cited by 43
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k